The compound cis-(dichloro)tetrammineruthenium(III) chloride induces caspase-mediated apoptosis in K562 cells

Toxicology in Vitro

Volumn 24, Issue 6, 2010, Pages 1562-1568

  de Lima, Aliny Pereira ^a   de Castro Pereira, Flávia ^a   Vilanova Costa, Cesar Augusto Sam Tiago ^a   Mariana dos Santos Mello, Francyelli ^a   de Santana Braga Barbosa Ribeiro, Alessandra ^a   Benfica, Polyana Lopes ^a   Valadares, Marize Campos ^a   Pavanin, Luiz Alfredo ^b   dos Santos, Wagner Batista ^c   de Paula Silveira Lacerda, Elisângela ^a  

^a FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c Faculdade Patos de Minas FPM   (Brazil)

Author keywords

Apoptosis; Cis (dichloro)tetrammineruthenium(III) chloride; Cytotoxicity; K562; MRC 5

Indexed keywords

(DICHLORO)TETRAMMINERUTHENIUM CHLORIDE; CASPASE 3; CASPASE 8; CASPASE 9; RUTHENIUM COMPLEX; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL STRAIN K 562; CONTROLLED STUDY; DNA CONTENT; DRUG CYTOTOXICITY; DRUG STRUCTURE; FIBROBLAST; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; MEMBRANE PERMEABILITY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL CYCLE; CELL SURVIVAL; CYCLOSPORINE; HUMANS; K562 CELLS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; RUTHENIUM COMPOUNDS; TETRAZOLIUM SALTS; THIAZOLES; TRYPAN BLUE; TUMOR STEM CELL ASSAY;

EID: 77956179446     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2010.06.015     Document Type: Article

References (43)

1. Alama A., Tasso B., Novelli F., Sparatore F. Organometallic compound in oncology: implications of novel organotins as antitumor agents. Drug Discovery Today 2009, 14:500-508.
2. Alberts B., Johnson A., Lewis J., Raff M., Roberts K., Watson J.D. Molecular Biology of the Cell 2004, Garland Science, New Work, p. 1463. 4 ed.
3. Allardyce C.S., Dyson P.J. Ruthenium in medicine: current clinical uses and future prospects. Platinum Metals Review 2001, 45:62-69.
4. Antonsson B., Montessuit S., Lauper S., Eskers R., Martinou J.C. Bax oligomerization is required for channel-forming activity in liposomes and to trigger cytochrome c release from mitochondria. Biochemical Journal 2000, 345:271-278.
5. Bedi A., Barber J.P., Bedi G.C., el-Deiry W.S., Sidransky D., Vala M.S., Akhtar A.J., Hilton J., Jones R.J. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 1995, 86:1148-1158.
6. Bergamo A., Gagliardi R., Scarcia V., Furlani A., Alessio E., Mestroni G., Sava G. In vitro cell cycle arrest, in vivo action on solid metastasizing tumors and host toxicity of the antimetastatic drug NAMI-A and cisplatin. Journal of Pharmacology and Experimental Therapeutics 1999, 289:559-564.
7. Brabec V., Nováková O. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity. Drug Resistance Updates 2006, 9:111-122.
8. Brenes O., Arce F., Gatjens-Boniche O., Díaz D. Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: possible mechanisms of cell resistance. Biomedicine and Pharmacotherapy 2007, 61:347-355.
9. Capozzi I., Katiuscia C., Cocchietto M., Salerno G., Bergamo A., Sava G. Modification of cell cycle and viability of TLX5 lymphoma in vitro by sulfoxide-ruthenium compounds and cisplatin detected by flow cytometry. Chemico-Biological Interactions 1998, 113:51-64.
10. Chatterjee S., Kundu S., Bhattacharya A., Christian G., Hartinger C.G., Dyson P.J. The ruthenium(II)-arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways. JBIC Journal of Biological Inorganic Chemistry 2008, 13:1149-1155.
11. Clarke M.J. Ruthenium metallopharmaceuticals. Coordination Chemistry Reviews 2003, 236:209-233.
12. Cohen G.M. Caspases: the executioners of apoptosis. Biochemical Journal 1997, 326:1-16.
13. De Giorgi F., Lartigue L., Bauer M.K.A., Schubert A., Grimm S., Hanson G.T., Remington S.J., Youle R.J., Ichas F. The permeability transition pore signals apoptosis by directing Bax translocation and multimerization. FASEB Journal 2002, 16:607-609.
14. Deininger M.W.N., Goldman J.M., Melo J.V. The molecular biology of chronic myeloid leukemia. Blood 2000, 96:3343-3356.
15. Djinovic V.M., Todorovic T., Zizak Z., Sabo T.J., Juranic A.D. Ru(III) complexes derived from N-methyl derivatives of glycine and 1, 3-propylenediamine-N, N'-diacetato ligands and their activities against HeLa, K562 cell lines and human PBMC. Journal of Coordination Chemistry 2009, 62:328-336.
16. Fernandez-Luna J.L. Bcr-Abl and inhibition of apoptosis in chronic myelogenous leukemia cells. Apoptosis 2000, 5:315-318.
17. 4RuCl. Journal of Inorganic Biochemistry 2001, 83:139-149.
18. Gaiddon P., Jeanequin P., Bischoff M., Pfeffer M., Loeffler J.P. Ruthenium (II)-derived organometallic compounds induce cytostatic and cytotoxic effects on mammalian cancer cell lines through p53-dependent and p53-independent mechanisms. The Journal of Pharmacology and Experimental Therapeutics 2005, 35:1403-1411.
19. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
20. Gross A., Jockel J., Wei M.C., Korsmeyer S.J. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO Journal 1998, 17:3878-3885.
21. Hantschel O., Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nature Reviews Molecular Cell Biology 2004, 5:33-44.
22. Hartinger C.G., Zorbas-Seifried S., Jakupec M.A., Kynast B., Zorbas H., Keppler B.K. From bench to beside- preclinical and early clinical development of the anticancer agent indazolium trans- [tetrachlorobis (1 H-indazazole)ruthenate (III)] KP1019 or FFC14A). Journal of Inorganic Biochemistry 2006, 100:891-904.
23. Jakupec M.A., Galanski M., Arion V.B., Hartinger C.G., Keppler B.K. Antitumor metal compounds: more than theme and variations. Dalton Transactions 2008, 183:194.
24. Jirsova K., Mandys V., Gispen W.H., Bar P.R. Cisplatin-induced apoptosis in cultures of human Schwann cell. Neuroscience Letters 2006, 392:22-26.
25. Kapitza S., Pongratz M., Jakupec M.A., Heffeter P., Berger W., Lackinger L., Keppler B.K., Marian B. Heterocyclic complexes of ruthenium (III) induce apoptosis in colorectal carcinoma cells. Journal of Cancer Research and Clinical Oncology 2005, 131:101-110.
26. Kapitza S., Jakupec M.A., Uhl M., Keppler B.K., Marian B. The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells. Cancer Letters 2005, 226:115-121.
27. Kartalou M., Essigmann J.M. Mechanisms of resistance to cisplatin. Mutation Research 2001, 478:23-43.
28. Kaufmann S.H., Earnshaw W.C. Induction of apoptosis by cancer chemotherapy. Experimental Cell Research 2000, 256:42-49.
29. Kaufmann S.H., Hengartner M.O. Programmed cell death: alive and well in the new millennium. Trends in Cell Biology 2001, 11:526-534.
30. Kostova I. Ruthenium as anticancer agents. Current Medicinal Chemistry 2006, 13:1085-1107.
31. Lakahai J.M.R., Bongard D.V.D., Pluim D., Beijnen J.H., Schellens J.H.M. A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. Clinical Cancer Research 2004, 10:3717-3727.
32. le Coutre P., Tassi E., Varella-Garcia M., Barni R., Mologni L., Cabrita G., Marchesi E., Supino R., Gambacorti-Passerini C. Induction of resistance to the Abelson inhibitor imatinib in human leukemic cells through gene amplification. Blood 2000, 95:1758-1766.
33. Menezes C.S.R., Gebrim L.C., Ávila V.M.R., Ferreira M.J., Vieira C.U., Pavanin L.A., Homsi-brandeburgo M.I., Hamaguchi A., Silveira-Lacerda E.P. Analysis in vivo of antitumor activity, Cytotoxicity and Interaction between plasmid DNA and the cis-dichlorotetramineruthenium (III) chloride. Chemico-Biological Interactions 2007, 167:116-124.
34. Mosman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation an cytotoxicity assays. Journal of Immunological Methods 1983, 16:55-63.
35. 2+ spectra and reduction potentials. Inorganic Chemistry 1985, 24:4444-4446.
36. Pizarro, A.M., Sadler, P.J., 2009. Unsual DNA modes for metal anticancer complexes. Biochimie doi: 10.1016.
37. Ribeiro A.S.B.B., da Silva C.C., Pereira F.C., Lima A.P., Vilanova-Costa C.A.S.T., Aguiar S.S., Pavanin L.A., da Cruz A.D., Silveira-Lacerda E.P. Mutagenic and genotoxic effects of cis-(dichloro)tetraammineruthenium(III) chloride on human peripheral blood lymphocytes. Biological Trace Element Research 2009, 130:249-261.
38. Sanna B., Debidda M., Pintus G., Tadolini B., Posadino A.M., Bennardini F., Sava G., Ventura C. The anti-metastatic agent imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate induces endothelial cell apoptosis by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase signaling pathway. Archives of Biochemistry and Biophysics 2002, 403:209-218.
39. Scolaro C., Bergamo A., Brescacin L., Delfino R., Cocchietto M., Laurenczy G., Geldbach J., Sava G., Dyson P.J. In vitro e in vivo evaluation of ruthenium (II)- arene PTA complexes. Journal of Medicinal Chemistry 2005, 48:4161-4171.
40. Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. Molecular Cell 2002, 9:459-470.
41. Silveira-Lacerda, E.P., Vilanova-costa, C.A.S.T., Hamaguchi, A., Pavanin, L.A., Goulart, L.R., Homsi-brandenburgo, M.I., Santos, W.B., Soares, A.M., Nomizo, A., 2010a. The ruthenium complex cis-(Dichloro)tetraammineruthenium(III) chloride presents selective cytotoxicity against murine B cell lymphoma (A-20), murine ascitic sarcoma 180 (S-180), human breast adenocarcinoma (SK-BR-3), and human T cell leukemia (Jurkat) tumor cell lines. Biological Trace Element Research.
42. Silveira-Lacerda, E.P., Vilanova-costa, C.A.S.T., Pereira, F.C, Hamaguchi, A., Pavanin, L.A., Goulart, L.R., Homsi-brandenburgo, M.I., Santos, W.B., Soares, A.M., Nomizo, A., 2010b. The ruthenium complex cis-(Dichloro) tetraammineruthenium(III) chloride presents immune stimulatory activity on human peripheral blood mononuclear cells. Biological Trace Element Research.
43. Vilaplana R.A., Delmani F., Manteca C., Torreblanca J., Moreno J., García-Herdugo G., González-Vílchez F. Synthesis, interaction with double-helical DNA and biological activity of the water soluble complex cis-dichloro-1, 2-propylenediamine-N, N, N', N'-tetraacetato ruthenium (III) (RAP). Journal of Inorganic Biochemistry 2006, 100:1834-1841.